Abstract
Rituximab is a human/mouse chimeric monoclonal antibody against CD20 antigen of B cells. It is one of the earliest monoclonal antibodies successfully used in the treatment of malignant tumors. In recent years, a number of studies have shown that rituximab can induce apoptosis of CD20-expressing B lymphocytes through antibody-dependent cytotoxicity, complement-dependent cytotoxicity and direct apoptosis induction. Combined with chemotherapy, rituximab can significantly enhance the therapeutic effect on aggressive lymphoma. In addition, rituximab is also play an increasingly important role in the treatment of primary immune thrombocytopenia, autoimmune hemolytic anemia and other autoimmune diseases, neuromyelitis optica, and lymphocytic proliferative diseases after stem cell transplantation. Key words: Hematologic diseases; Lymphoma; Hematopoietic stem cell transplantation; Rituximab
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
